Receptos Inc. moved one step closer to its goal of setting a safer standard in oral therapy for multiple sclerosis (MS), reporting positive data from a planned interim analysis of the Phase II portion of RADIANCE, the company’s Phase II/III trial of RPC1063 in relapsing MS. (See BioWorld Insight, Nov. 4, 2013.)